MARKETS / COMPANIES / ECONOMYRSS edition ↗
Dividend Brief
Market News

Goyal discusses investment opportunities with Bayer, Fresenius

SENSEX 72,789.24 -460.15 NIFTY 22,479.45 -208.20 CRUDEOIL 9,572.00 + 88.00 GOLD 142,773.00 -536.00 SILVER 196,903.00 -2,696.00 SENSEX 72,789.24 -460.15 NIFTY 22,479.45 -208.20 NIFTY 22,479.45 -208.20 CRUDEOIL 9,572.00 +…

Goyal discusses investment opportunities with Bayer, Fresenius
SENSEX 72,789.24

 -460.15

NIFTY 22,479.45

 -208.20

CRUDEOIL 9,572.00

+ 88.00

GOLD 142,773.00

 -536.00

SILVER 196,903.00

 -2,696.00

SENSEX 72,789.24

 -460.15

NIFTY 22,479.45

 -208.20

NIFTY 22,479.45

 -208.20

CRUDEOIL 9,572.00

+ 88.00

CRUDEOIL 9,572.00

+ 88.00

GOLD 142,773.00

 -536.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

Goyal said he discussed Bayer's expansion plans in India and opportunities to deepen its engagement with the country's robust healthcare ecosystem through greater investment, innovation and collaboration

By PTI

Updated - October 23, 2026 at 11:46 AM. | Berlin

Stefan Oelrich, President of the Pharmaceuticals Division at Bayer

Commerce and Industry Minister Piyush Goyal has held meetings with senior executives of pharmaceutical major Bayer and healthcare group Fresenius to discuss investment opportunities in India.

During his meeting with Stefan Oelrich, President of the Pharmaceuticals Division at Bayer, Goyal said he discussed Bayer's expansion plans in India and opportunities to deepen its engagement with the country's robust healthcare ecosystem through greater investment, innovation and collaboration.

"Had a fruitful meeting with Mr. Michael Sen, CEO of Fresenius Group. Discussed opportunities to deepen collaboration in healthcare, leveraging India's rapidly expanding healthcare sector, growing demand for quality and affordable medical solutions, and strong manufacturing capabilities," Goyal said in a social media post.

Held a meeting with Mr. Stefan Oelrich, President of the Pharmaceuticals Division at Bayer. Discussed Bayer's expansion plans in India & opportunities to deepen its engagement in our robust healthcare ecosystem through greater investment, innovation & collaboration. https://t.co/cnNNiMA9kK

— Piyush Goyal (@PiyushGoyal) October 23, 2026

He explored how the group can harness India's skilled talent to serve both domestic and global markets.

During his meeting with Murat Akyildiz, Global General Partner at Knauf Group, Goyal discussed the company's expanding manufacturing operations in India and avenues to deepen collaboration in sustainable construction materials and infrastructure development.

Published on October 23, 2026

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!
  • Access 10 free stories per month
  • Get notified by email for early preview to new features, discounts & offers
Source: The Hindu BusinessLine — Companies ↗

Figures reflect the source report and its stated period. This article is for information and is not investment advice.